News Mustang Bio, Inc.

Equities

MBIO

US62818Q2030

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-31 pm EDT			5-day change	1st Jan Change
0.2012 ^USD	-4.82%		-4.14%	-85.10%

May. 15	Mustang Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
May. 02	Mustang Bio, Inc. announced that it has received $3.3 million in funding	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Mustang Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 15	CI
Mustang Bio Announces Closing of $4 Million Public Offering	May. 02	AQ
Mustang Bio, Inc. announced that it has received $3.3 million in funding	May. 01	CI
Mustang Bio Prices Public Offering of 16.9 Million Shares, Accompanying Warrants	Apr. 30	MT
Mustang Bio Announces Pricing of $4 Million Public Offering	Apr. 29	AQ
Mustang Bio : Results of Operations and Financial Condition - Form 8-K	Apr. 29	PU
Mustang Bio, Inc. announced that it expects to receive $3.3 million in funding	Apr. 28	CI
North American Morning Briefing : Stock Futures Rise Despite Middle East Tensions	Apr. 15	DJ
Mustang Bio : Costs Associated with Exit/Disposal - Form 8-K	Apr. 12	PU
Mustang Bio : Corporate Presentation	Apr. 01	PU
Mustang Bio Announces Vision for CAR T-Cell Therapy Platform Expansion into Autoimmune Diseases	Mar. 28	AQ
Mustang Bio, Inc Announces Vision for CAR T-Cell Therapy Platform Expansion into Autoimmune Diseases	Mar. 28	CI
Mustang Bio Reports Full-Year 2023 Financial Results and Recent Corporate Highlights	Mar. 11	AQ
Mustang Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 11	CI
City of Hope-developed chimeric antigen receptor T cell therapy shows clinical activity in patients with aggressive brain tumors in a Phase 1 trial	Mar. 08	AQ
Mustang Bio Announces Publication in Nature Medicine of Data from Phase 1 Trial Evaluating MB-101 IL13Rα2-targeted CAR T-Cells in High-Grade Glioma	Mar. 07	AQ
Mustang Bio, Inc. Announces Publication in Nature Medicine of Data from Phase 1 Trial Evaluating MB-101IL13Ra2-targeted CAR T-Cells in High-Grade Glioma	Mar. 07	CI
Mustang Bio : Corporate Presentation	Mar. 01	PU
Mustang Bio, Inc Appoints James Murphy as Interim Chief Financial Officer	Jan. 25	CI
Mustang Bio to Participate in the B. Riley Securities 4th Annual Oncology Conference	Jan. 11	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Mustang Bio, Inc.

Equities

MBIO

US62818Q2030

Summary

Filters